In recent months there have been congressional hearings examining alleged anticompetitive patenting practices currently barring biosimilar competition. One potential action that could be taken is to allow the FTC to clear certain market access barriers that are halting biosimilar competition, including the patent thickets protecting market exclusivity after the originator's central composition-of-matter patent has expired.
By Michelle Scott, Chris Brampton, Ph.D., and Kelly Kroeger, Ph.D.,Bio-Rad Laboratories, Inc.
Flow cytometry is an important tool for the diagnosis and classification of leukemia. While many leukocyte markers have been identified, and are used to determine the exact subtypes of leukemia a patient may have, high-dimensional multicolor analysis has been limited by instrument capabilities. This has often resulted in splitting a valuable limited sample into multiple independent tests to fully define the patient’s phenotype.
Biacore SPR assays provide an automated and reproducible real-time determination of active concentrations that can be considered an alternative to a traditional ELISA approach. This article provides general guidance on how to convert an existing ELISA assay to a Biacore SPR-assay and, by doing so, shows how you can get results in less than half the time compared with ELISA.